Skip to content
drillr.ai
Sign up

MBRX

Moleculin Biotech, Inc.

NASDAQ · Healthcare · Biotechnology · US

$6.19
+16.79%
Ask drillr

  • Oct 16, 2026, 13:20 UTC

    Moleculin Biotech filed an amendment to its certificate of incorporation to effect a 1-for-20 reverse stock split of its common stock.

    Source:

  • Oct 9, 2026, 21:24 UTC

    Moleculin Biotech elected Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco and Elizabeth A. Cermak as directors.

  • Sep 28, 2026, 11:00 UTC

    Moleculin Biotech announced the publication of a peer-reviewed cardiac safety analysis of Annamycin in Frontiers in Cardiovascular Medicine, reporting no cardiotoxicity across five pooled clinical trials.

    Source:

  • Sep 23, 2026, 12:25 UTC

    Moleculin Biotech secured a Mexican patent protecting its lung-targeted liposomal Annamycin formulation through 2040.

    Source:

  • Sep 18, 2026, 21:07 UTC

    Moleculin Biotech, Inc. received a Nasdaq notice dated September 15, 2026 for failing to comply with the minimum bid price requirement under Rule 5550(a)(2) and intends to request a hearing before the Nasdaq Hearings Panel.

  • Sep 14, 2026, 12:35 UTC

    Moleculin announced it will present new Annamycin data at the AACR Conference on Pancreatic Cancer and two European scientific meetings.

    Source:

  • Aug 14, 2026, 12:30 UTC

    Moleculin Biotech reported financial results for the second quarter ended June 30, 2026, and highlighted progress in its pivotal MIRACLE trial for Annamycin in relapsed/refractory AML.

    Source:

  • Jul 31, 2026, 14:12 UTC

    Moleculin Biotech priced a best-efforts public offering of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 37,130,001 shares at a combined price of $0.75 per share, expected to close on or about August 3, 2026.

    Source:

  • Jul 31, 2026, 12:10 UTC

    Moleculin Biotech reported positive interim data from its MIRACLE R/R AML trial, showing a blinded CRc of 37% in venetoclax-failed patients, with enrollment at 74 of 90 patients and final Part A treatment expected in September 2026.

    Source:

  • Jun 30, 2026, 12:30 UTC

    Moleculin Biotech announced positive interim results from its Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia.

    Source: